This is the final version of the article. Available from Royal College of General Practitioners via the DOI in this record.BACKGROUND: Variation in cancer survival persists between comparable nations and appears to be due, in part, to primary care practitioners (PCPs) having different thresholds for acting definitively in response to cancer-related symptoms. AIM: To explore whether cancer guidelines, and adherence to them, differ between jurisdictions and impacts on PCPs' propensity to take definitive action on cancer-related symptoms. DESIGN AND SETTING: A secondary analysis of survey data from six countries (10 jurisdictions) participating in the International Cancer Benchmarking Partnership. METHOD: PCPs' responses to five clinical vigne...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Background Variation in cancer survival persists between comparable nations and appears to be due, i...
Background Variation in cancer survival persists between comparable nations and appears to be due, i...
OBJECTIVES: The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 co...
bjectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 coun...
Background: Survival rates following a diagnosis of cancer vary between countries. ...
Background The International Cancer Benchmarking Partnership (ICBP), is a collaboration between six...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...
Objectives: Cancer survival rates vary widely between European countries, with differences in timeli...
OBJECTIVES: Cancer survival and stage of disease at diagnosis and treatment vary widely across Europ...
Objectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 cou...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Background Variation in cancer survival persists between comparable nations and appears to be due, i...
Background Variation in cancer survival persists between comparable nations and appears to be due, i...
OBJECTIVES: The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 co...
bjectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 coun...
Background: Survival rates following a diagnosis of cancer vary between countries. ...
Background The International Cancer Benchmarking Partnership (ICBP), is a collaboration between six...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...
Objectives: Cancer survival rates vary widely between European countries, with differences in timeli...
OBJECTIVES: Cancer survival and stage of disease at diagnosis and treatment vary widely across Europ...
Objectives The International Cancer Benchmarking Partnership (ICBP) is a collaboration between 6 cou...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...
Objectives Cancer survival rates vary widely between European countries, with differences in timelin...
Objectives Cancer survival and stage of disease at diagnosis and treatment vary widely across Europe...